October 09, 2016
2 min read
Save

Atezolizumab prolongs OS in previously treated NSCLC

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

COPENHAGEN, Denmark — Atezolizumab significantly extended OS compared with docetaxel in patients receiving second-line or third-line treatment for non–small cell lung cancer, according to results of the primary analysis of the phase 3 OAK study presented at the European Society for Medical Oncology Congress.

Patients benefited from treatment with atezolizumab (Tecentriq, Genentech) regardless of their PD-L1 expression and disease histology.

The phase 3 OAK study is the first study assessing a PD-L1 antibody in NSCLC, and this is also the largest phase 3 trial in the second line looking at the assessment of checkpoint inhibitors,” Fabrice Barlesi, MD, PhD, head of multidisciplinary oncology and therapeutic innovations department at Aix-Marseille University and Assistance Publique Hôpitaux de Marseille in France, said during a press conference.

The analysis included data from 1,225 patients stratified by PD-L1 status, number of prior chemotherapy regimens (1 vs. 2) and histology. Fifty-five percent of patients met the criteria for PD-L1 positivity, or at least 1% of PD-L1 expression in tumor cells (TC) or tumor-infiltrating immune cells (IC).

Researchers randomly assigned patients 1:1 to receive 1,200 mg IV atezolizumab every 3 weeks or 75 mg/m2 IV docetaxel every 3 weeks.

OS in the intent-to-treat population, as well as in PD-L1–expressing patients, served as the co-primary endpoints. Secondary endpoints included PFS, overall response rate, duration of response and safety.

Researchers conducted the primary efficacy analysis in the first 850 patients (median age, 64 years; 61% men) enrolled. Twenty-five percent of patients had received two prior lines of therapy, 26% had squamous histology, 67% were past smokers and 37% had a performance status of 0.

In the intent-to-treat population, median OS was 13.8 months with atezolizumab compared with 9.6 months with docetaxel (HR = 0.73; 95% CI, 0.62-0.87).

“The curves separated early and remained separated over time,” Barlesi said. “There also was a clinically meaningful improvement in median OS of 4 months for patients receiving the PD-L1 inhibitor.”

Atezolizumab improved OS regardless of PD-L1 expression levels. Patients with any level of expression, or TC 1/2/3 or IC 1/2/3, achieved a median OS of 15.7 months with atezolizumab compared with 10.3 months with docetaxel (HR = 0.74; 95% CI, 0.58-0.93).

The HRs ranged from 0.75 (95% CI, 0.59-0.96) among patients with TC 0 and IC 0 — or no PD-L1 expression — to 0.41 (95% CI, 0.27-0.64) in patients with TC 3 or IC 3, the highest level of expression.

Atezolizumab also conferred longer survival in patients with squamous histology (8.9 months vs. 7.7 months; HR = 0.73; 95% CI, 0.54-0.98) and nonsquamous histology (15.6 months vs. 11.2 months; HR = 0.73; 95% CI, 0,6-0.89).

The ORR was 13.6% with atezolizumab and 13.4% with docetaxel. Median PFS was 2.8 months with atezolizumab and 4 months with docetaxel.

Median duration of treatment was longer with atezolizumab (16.3 months vs. 6.2 months).

Still, fewer patients treated with atezolizumab experienced a treatment-related grade 3 or grade 4 adverse event (15% vs. 43%), treatment-related grade 5 adverse event (0% vs. 0.2%), or an adverse event that led to treatment withdrawal (8% vs. 19%) or dose modification or delay (25% vs. 36%).

“The goal of treatment is to allow the immune system to control and possibly eliminate cancer cells, so atezolizumab might be useful in a very large setting of different cancers,” Barlesi said in a press release. – by Alexandra Todak

Reference:

Barlesi F, et al. Abstract LBA44_PR. Presented at: European Society for Medical Oncology Congress; Oct. 7-11, 2016; Copenhagen, Denmark.

Disclosure: F. Hoffmann-La Roche funded this study. Barlesi reports no relevant financial disclosures. Please see the abstract for a list of all other researchers’ relevant financial disclosures.